Salivary gland tumors as secondary malignancies after treatment for pediatric bone sarcoma.

J. Kreshak,C. Ferrari,G. Bacci,M. Gambarotti,S. Ferrari,M. Mercuri,A. Longhi

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.e19666

IF: 45.3

2011-05-20

Journal of Clinical Oncology

Abstract:e19666 Background: Osteosarcoma and Ewing's sarcoma are bone sarcomas that primarily affect children and young adults. The advent of chemotherapy greatly improved long term survival rates, however, they have been found to have high rates of secondary malignant neoplasms, likely due to aggressive multimodality treatment and radiation therapy. The most frequent second malignancies noted in the literature are CNS tumors, breast cancer, leukemia, and sarcomas. Salivary gland tumors are rare as primaries; their incidence rises in the setting of prior cancer treatment. The objective of this retrospective study was to evaluate secondary salivary gland malignancies in patients previously treated for pediatric bone sarcomas in a single institution. METHODS We analyzed our database of 1376 patients treated for osteosarcoma or Ewing's sarcoma at a single institution from 1983-2008. Of 39 secondary malignancies found, 6 were salivary gland tumors. These charts were retrospectively reviewed for histology, respective dates, and treatment protocols. RESULTS Of 1376 patients, 883 were treated for osteosarcoma, 493 for Ewing's sarcoma. 39 secondary malignancies were found (2.8%); 6 of these were salivary gland tumors (15.3%) (4 after treatment for osteosarcoma, 2 after Ewing's sarcoma). Median patient age was 13 years (10-27); all were treated with chemotherapy, none with head or neck radiation. Median interval between the two diagnoses was 65 months (48-97). 5 salivary gland tumors were mucoepidermoid carcinoma of the parotid gland and 1 was acinic cell carcinoma of a submandibular gland. 4 tumors were low grade, 1 intermediate grade, 1 high grade. All were treated with surgery alone; all patients were free of both diseases at last follow-up (median follow-up post diagnosis of secondary malignancy: 57 months; range 18-179). CONCLUSIONS In our series, secondary salivary gland cancers in patients previously treated for bone sarcomas were seen at a higher rate than is observed for these cancers as primaries and were unusually frequent relative to other forms of secondary malignancy (third most common). In young patients previously treated with chemotherapy, painless swelling of a salivary gland should always be considered suspicious.